Peptide receptor radionuclide therapy with 177Lu labeled somatostatin analogs DOTATATE and DOTATOC: Contrasting renal dosimetry in the same patient

Recent Results in Cancer Research

Volumn 194, Issue , 2013, Pages 551-559

  Kulkarni, Harshad R ^a   Schuchardt, Christiane ^a   Baum, Richard P ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

DOTATATE; DOTATOC; Mean absorbed dose

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; LUTETIUM TETRAXETAN OCTREOTIDE LU 177; LUTETIUM TETRAXETAN OCTREOTIDE[3 TYROSINE] LU 177; NITROGEN; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; UREA;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOSIMETRY; DRUG UPTAKE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY TUBULE EXCRETION; MALE; MEAN RESIDENCE TIME; METASTASIS; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE THERAPY; RENAL PROTECTION; RISK ASSESSMENT; RISK FACTOR; UREA NITROGEN BLOOD LEVEL;

EID: 84867095384     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27994-2_32     Document Type: Article

References (20)

1. Arora P, Verrelli M, Mulloy LL, Talavera F, Aronoff GR, Schmidt RJ, Batuman V. Chronic Renal failure. eMedicine Medscape references Feb 2012. http://emedicine.medscape.com/article/238798-overview
2. Behr TM, Goldenberg DM, Becker W (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med 25:201-212 (Pubitemid 28130048)
3. Bodei L, Cremonesi M, Zoboli S (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med 30:207-216 (Pubitemid 36686839)
4. Bodei L, Cremonesi M, Ferrari M, Pacifi C, Grana C, Bartolomei M, Baio S, Sansovini M, Paganelli G (2008) Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors. Eur J Nucl Med 35(10):1847-1856
5. Bolch WE, Eckerman KF, Sgouros G, Thomas SR (2009) MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med 50:477-484
6. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G (2006) Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 47(9):1467-1475 (Pubitemid 47544933)
7. De Jong M, Bakker WH, BreemanWAet al (1998) Pre-clinical comparison of [DTPA0] octreotide, [DTPA0, Tyr3] octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostatin receptortargeted scintigraphy and radionuclide therapy. Int J Cancer 75:406-411
8. De Jong M, Valkema R, Jamar F (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 32:133
9. Esser JP, Krenning EP, Teunissen JJM (2006) Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu-DOTA0, Tyr3] octreotide: which peptide is preferable for PRRT? Eur J Nucl Med 33:1346-1351
10. Forrer F, Uusijärvi H, Waldherr C (2004) A comparison of 111In-DOTATOC and 111In-DOTATATE: Biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med 31:1257-1262 (Pubitemid 39222489)
11. Helisch A, Förster GJ, Reber H (2004) Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med 31:1386-1392 (Pubitemid 39361934)
12. Jamar F, Barone R, Matthieu I et al (2003) 86Y-DOTA0-D-Phe1-Tyr3- octreotide (SMT487) - a phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regiments of amino acid coinfusion. Eur J Nucl Med 30:510
13. Kwekkeboom DJ, Mueller-Brand J, Paganelli G (2005a) An overview of the results of peptide receptor radionuclide therapy with 3 different radiolabeled somatostatin analogues. J Nucl Med 46:62S
14. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005b) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]-octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754
15. Lambert B, Cybulla M, Weiner SM et al (2004) Renal toxicity after radionuclide therapy. Radiat Res 161:607-611 (Pubitemid 40754231)
16. National Chronic Kidney Disease Fact Sheet (2010) CDC website. http://www.cdc.gov/diabetes/pubs/factsheets/kidney.htm
17. Otte A, Mueller-Brand J, Dellas S (1998) Yttrium-90 labeled somatostatin analogue for cancer treatment. Lancet 351:417
18. Pauwels S, Barone R, Walrand S et al (2005) Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs. J Nucl Med 46(suppl 1):92S-98S (Pubitemid 47619024)
19. Valkema R, Pauwels SA, Kvols LK et al (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 46(suppl 1):83S-91S (Pubitemid 47619023)
20. Wehrmann C, Senftleben S, Zachert C, Mueller D, Baum RP (2007) Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 22(3):406-416 (Pubitemid 47067899)